Recruiting studies: Metastatic Alk Non Small Cell Lung Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients
Phase N/A · 1 location(s) · Sichuan Cancer Hospital and Research Institute · NCT06361589 A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangement
Phase 1/Phase 2 · 165 location(s) · Turning Point Therapeutics, Inc. · NCT03093116 A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small
Phase 2 · 9 location(s) · Centro di Riferimento Oncologico - Aviano · NCT06378892 Post Marketing Surveillance(PMS) Study of Lorviqua in Korea
Phase N/A · 1 location(s) · Pfizer · NCT05599412 A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Phase 1/Phase 2 · 5 location(s) · 7 Hills Pharma, LLC · NCT06362369 A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advance
Phase 3 · 287 location(s) · AstraZeneca · NCT06627647 A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
Phase 1 · 16 location(s) · Astellas Pharma Global Development, Inc. · NCT07140016 Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally
Phase N/A · 1 location(s) · Guangdong Association of Clinical Trials · NCT07696832 A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer
Phase 1/Phase 2 · 6 location(s) · Memorial Sloan Kettering Cancer Center · NCT06007937 A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic
Phase 3 · 296 location(s) · AstraZeneca · NCT06868277

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.